Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$18.78 -6.1%	$16.63	$9.57 ▼ $27.34	$2.76B	0.94	2.27 million shs	5.00 million shs
CNTA Centessa Pharmaceuticals	$17.64 +2.9%	$14.64	$9.60 ▼ $19.09	$2.30B	1.48	1.12 million shs	890,003 shs
HHH Howard Hughes	$73.45 -1.5%	$69.53	$61.40 ▼ $87.77	$4.43B	1.22	399,038 shs	399,392 shs
TSHA Taysha Gene Therapies	$2.94 -3.0%	$2.60	$1.05 ▼ $3.31	$650.42M	0.98	2.88 million shs	2.82 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	-6.05%	+16.94%	+6.52%	+19.54%	-17.27%
CNTA Centessa Pharmaceuticals	+2.92%	+2.68%	+16.98%	+41.01%	+40.00%
HHH Howard Hughes	-1.62%	+4.48%	+6.90%	+4.01%	+4.38%
TSHA Taysha Gene Therapies	-2.97%	+4.63%	+17.13%	+8.89%	+27.27%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARWR Arrowhead Pharmaceuticals	4.1449 of 5 stars	4.5	1.0	3.4	3.0	1.7	0.0
CNTA Centessa Pharmaceuticals	2.4688 of 5 stars	3.5	1.0	0.0	1.9	3.3	0.6
HHH Howard Hughes	1.7406 of 5 stars	1.3	4.0	0.0	1.7	3.3	1.3
TSHA Taysha Gene Therapies	3.5131 of 5 stars	4.5	2.0	0.0	3.0	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	3.00	Buy	$43.14	129.73% Upside
CNTA Centessa Pharmaceuticals	3.00	Buy	$28.10	59.30% Upside
HHH Howard Hughes	2.67	Moderate Buy	$80.33	9.37% Upside
TSHA Taysha Gene Therapies	3.00	Buy	$8.29	181.83% Upside

Current Analyst Ratings Breakdown

Latest TSHA, HHH, CNTA, and ARWR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	TSHA Taysha Gene Therapies	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$7.50 ➝ $8.00
8/12/2025	CNTA Centessa Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
8/12/2025	TSHA Taysha Gene Therapies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $10.00
8/11/2025	ARWR Arrowhead Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/11/2025	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00
8/8/2025	ARWR Arrowhead Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$40.00 ➝ $38.00
7/30/2025	CNTA Centessa Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
7/28/2025	ARWR Arrowhead Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/21/2025	CNTA Centessa Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
7/11/2025	TSHA Taysha Gene Therapies	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
7/1/2025	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$3.55M	731.41	N/A	N/A	$3.76 per share	4.99
CNTA Centessa Pharmaceuticals	$6.85M	345.25	N/A	N/A	$2.57 per share	6.86
HHH Howard Hughes	$1.75B	2.49	$9.55 per share	7.69	$47.55 per share	1.54
TSHA Taysha Gene Therapies	$8.33M	75.76	N/A	N/A	$1.16 per share	2.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.28	N/A	N/A	76.81	N/A	-40.91%	-11.62%	N/A
CNTA Centessa Pharmaceuticals	-$235.76M	-$1.79	N/A	N/A	N/A	N/A	-40.39%	-29.87%	N/A
HHH Howard Hughes	$200.55M	$4.57	16.07	79.84	N/A	12.85%	10.51%	3.15%	N/A
TSHA Taysha Gene Therapies	-$89.30M	-$0.34	N/A	N/A	N/A	-1,144.97%	-78.44%	-44.82%	N/A

Latest TSHA, HHH, CNTA, and ARWR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	CNTA Centessa Pharmaceuticals	-$0.35	-$0.38	-$0.03	-$0.38	$0.63 million	N/A
8/12/2025	Q2 2025	TSHA Taysha Gene Therapies	-$0.07	-$0.09	-$0.02	-$0.09	$1.61 million	$1.99 million
8/7/2025	Q3 2025	ARWR Arrowhead Pharmaceuticals	-$0.94	-$1.26	-$0.32	-$1.26	$29.01 million	$27.77 million
5/15/2025	Q1 2025	TSHA Taysha Gene Therapies	-$0.08	-$0.08	N/A	-$0.08	$1.48 million	$2.30 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CNTA Centessa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HHH Howard Hughes	N/A	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	0.39	4.87	4.87
CNTA Centessa Pharmaceuticals	0.28	14.37	14.37
HHH Howard Hughes	1.85	1.18	1.41
TSHA Taysha Gene Therapies	0.77	5.35	5.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
CNTA Centessa Pharmaceuticals	82.01%
HHH Howard Hughes	93.83%
TSHA Taysha Gene Therapies	77.70%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
CNTA Centessa Pharmaceuticals	7.09%
HHH Howard Hughes	33.00%
TSHA Taysha Gene Therapies	3.78%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.26 million	132.31 million	Optionable
CNTA Centessa Pharmaceuticals	200	134.07 million	124.15 million	Optionable
HHH Howard Hughes	608	59.40 million	39.80 million	Optionable
TSHA Taysha Gene Therapies	180	214.66 million	206.55 million	Optionable

TSHA, HHH, CNTA, and ARWR Headlines

Recent News About These Companies

Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $8.00

2 hours ago | americanbankingnews.com

Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $10.00

August 14 at 6:17 PM | marketbeat.com

Taysha Gene Therapies price target raised to $14 from $11 at Canaccord

August 13 at 12:54 AM | msn.com

4TSHA : A Glimpse Into The Expert Outlook On Taysha Gene Therapies Through...

August 13 at 12:54 AM | benzinga.com

Taysha Gene Therapies (NASDAQ:TSHA) Issues Earnings Results

August 13 at 2:29 PM | marketbeat.com

Taysha Gene Therapies Inc (TSHA) Q2 2025 Earnings Call Highlights: Regulatory Milestones and ...

August 13 at 6:13 AM | finance.yahoo.com

XTX Topco Ltd Takes $282,000 Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

August 13 at 3:13 AM | marketbeat.com

Taysha Gene Therapies price target raised to $10 from $9 at Chardan

August 13 at 2:12 AM | msn.com

Taysha plans pivotal TSHA-102 trial enrollment in Q4 2025, extends cash runway to 2028

August 13 at 2:12 AM | msn.com

What's Next: Taysha Gene Therapies's Earnings Preview

August 13 at 2:12 AM | benzinga.com

Taysha Gene Therapies Advances Rett Syndrome Trials

August 12 at 12:25 AM | tipranks.com

Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Beats Revenue Estimates

August 12 at 4:01 PM | zacks.com

Taysha Gene Therapies, Inc. (TSHA) Q2 2025 Earnings Call Transcript

August 12 at 2:06 PM | seekingalpha.com

Taysha Gene Therapies, Inc. 2025 Q2 - Results - Earnings Call Presentation

August 12 at 1:39 PM | seekingalpha.com

Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 12 at 8:01 AM | globenewswire.com

Analysts Set Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Target Price at $8.17

August 11, 2025 | americanbankingnews.com

Taysha Gene Therapies (TSHA) Projected to Post Earnings on Tuesday

August 11, 2025 | americanbankingnews.com

Jefferies Financial Group Inc. Invests $341,000 in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

August 9, 2025 | marketbeat.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Recommendation of "Buy" by Brokerages

August 9, 2025 | marketbeat.com

Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12

August 5, 2025 | globenewswire.com

Taysha Gene Therapies (TSHA) Expected to Announce Earnings on Monday

August 5, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSHA, HHH, CNTA, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$18.78 -1.21 (-6.05%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$18.94 +0.16 (+0.85%)

As of 04:16 AM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Centessa Pharmaceuticals NASDAQ:CNTA

$17.64 +0.50 (+2.92%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$17.57 -0.07 (-0.40%)

As of 08/14/2025 05:02 PM Eastern

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Howard Hughes NYSE:HHH

$73.45 -1.10 (-1.48%)

Closing price 08/14/2025 03:59 PM Eastern

Extended Trading

$74.04 +0.58 (+0.80%)

As of 04:13 AM Eastern

Howard Hughes Holdings Inc., together with its subsidiaries, operates as a real estate development company in the United States. It operates in four segments: Operating Assets; Master Planned Communities (MPCs); Seaport; and Strategic Developments. The Operating Assets segment consists of developed or acquired retail, office, and multi-family properties along with other retail investments. Its MPCs segment develops, sells, and leases residential and commercial land designated for long-term community development projects in and around Las Vegas, Nevada; Houston, Texas; and Phoenix, Arizona. The Seaport segment is involved in the landlord operations, managed businesses, and events and sponsorships services of its restaurant, retail, and entertain properties in Pier 17, New York City; Historic Area/Uplands; and Tin Building, as well as in 250 Water Street and in the Jean-Georges restaurants. The Strategic Development segment develops and redevelops residential condominiums and commercial properties. It serves homebuilders. Howard Hughes Holdings Inc. was founded in 2010 and is headquartered in The Woodlands, Texas.

Taysha Gene Therapies NASDAQ:TSHA

$2.94 -0.09 (-2.97%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$2.99 +0.05 (+1.70%)

As of 08/14/2025 07:58 PM Eastern

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time